Abstract
Background: Recent findings indicate that incretin hormones and incretin-based therapies may affect the metabolism of lipoproteins, although the corresponding mechanisms are not clearly defined.
Objective: To summarize the available data on the mechanisms linking incretins with the characteristics of serum lipoproteins and discuss the clinical implications of these relationships.
Methods: PubMed was searched using the terms “incretins”, “GLP-1”, “GIP” and “lipids”, “dyslipidemia”, “triglycerides”, “apolipoprotein B48”. All articles published in the English language until June 2016 were assessed and the relevant information is presented here.
Results: GLP-1, and therapies that increase its activity, exert a beneficial effect on lipoprotein metabolism that is translated in a reduction in the fasting and postprandial concentration of triglycerides and a small improvement in the concentration and function of HDLs. In addition, a shift towards larger, less atherogenic particles usually follows the administration of GLP-1 receptor agonists. The mechanisms that underlie these changes involve a direct effect of GLP- 1 on the hepatic and intestinal production of triglyceride-rich lipoproteins, the GLP-1 induced increase in the production and function of insulin, the activation of specific areas of central nervous system as well as the increase in the peripheral utilization of triglycerides for energy production. On the other hand, GLP-2 increases the absorption of dietary fat and the production of triglyceride-rich lipoproteins while the role of GIP on lipid metabolism remains indeterminate.
Conclusion: GLP-1 and incretin-based therapies favorably affect lipid metabolism. These effects may contribute to the beneficial effects of incretin-based therapies on atherosclerosis and fatty liver disease.
Keywords: Incretins, GLP-1, GLP-2, GIP, triglycerides, HDL, dyslipidemia, lipids.
Current Medicinal Chemistry
Title:Incretins and Lipid Metabolism
Volume: 25 Issue: 18
Author(s): Vasilis Tsimihodimos *Moses Elisaf
Affiliation:
- Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina,Greece
Keywords: Incretins, GLP-1, GLP-2, GIP, triglycerides, HDL, dyslipidemia, lipids.
Abstract: Background: Recent findings indicate that incretin hormones and incretin-based therapies may affect the metabolism of lipoproteins, although the corresponding mechanisms are not clearly defined.
Objective: To summarize the available data on the mechanisms linking incretins with the characteristics of serum lipoproteins and discuss the clinical implications of these relationships.
Methods: PubMed was searched using the terms “incretins”, “GLP-1”, “GIP” and “lipids”, “dyslipidemia”, “triglycerides”, “apolipoprotein B48”. All articles published in the English language until June 2016 were assessed and the relevant information is presented here.
Results: GLP-1, and therapies that increase its activity, exert a beneficial effect on lipoprotein metabolism that is translated in a reduction in the fasting and postprandial concentration of triglycerides and a small improvement in the concentration and function of HDLs. In addition, a shift towards larger, less atherogenic particles usually follows the administration of GLP-1 receptor agonists. The mechanisms that underlie these changes involve a direct effect of GLP- 1 on the hepatic and intestinal production of triglyceride-rich lipoproteins, the GLP-1 induced increase in the production and function of insulin, the activation of specific areas of central nervous system as well as the increase in the peripheral utilization of triglycerides for energy production. On the other hand, GLP-2 increases the absorption of dietary fat and the production of triglyceride-rich lipoproteins while the role of GIP on lipid metabolism remains indeterminate.
Conclusion: GLP-1 and incretin-based therapies favorably affect lipid metabolism. These effects may contribute to the beneficial effects of incretin-based therapies on atherosclerosis and fatty liver disease.
Export Options
About this article
Cite this article as:
Tsimihodimos Vasilis *, Elisaf Moses, Incretins and Lipid Metabolism, Current Medicinal Chemistry 2018; 25 (18) . https://dx.doi.org/10.2174/0929867324666170414164244
DOI https://dx.doi.org/10.2174/0929867324666170414164244 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Secondary Metabolites in the Treatment of Diabetes Mellitus: A Paradigm Shift
Current Drug Metabolism Editorial:Genomics and Epigenomics of Tumor and Aging Cells
Current Genomics Baculovirus Gene Delivery: A Flexible Assay Development Tool
Current Gene Therapy Peroxisome Proliferator-Activated Receptor ?? (PPAR??) and Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Potential Use of Vanadium Compounds in Therapeutics
Current Medicinal Chemistry Clioquinol – A Novel Copper-Dependent and Independent Proteasome Inhibitor
Current Cancer Drug Targets Preface [Hot Topic: Obesity Drug Design (Executive Editor : Christian Weyer)].
Current Pharmaceutical Design Risk Factors Associated with Development of Pulmonary Arterial Hypertension and Corpulmonale in Patients with Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews C-Peptide and its Correlation to Parameters of Insulin Resistance in the Metabolic Syndrome
CNS & Neurological Disorders - Drug Targets Effect of a Dihydropyridine-Type Calcium Channel Blocker on Vascular Remodelling after Experimental Balloon Angioplasty
Cardiovascular & Hematological Agents in Medicinal Chemistry Reserpine Induces Apoptosis and Cell Cycle Arrest in Hormone Independent Prostate Cancer Cells through Mitochondrial Membrane Potential Failure
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Biotechnology Patent Selections
Recent Patents on DNA & Gene Sequences MMP-9, a Potential Target for Cerebral Ischemic Treatment
Current Neuropharmacology Pathophysiological Mechanisms Linking Type 2 Diabetes and Dementia: Review of Evidence from Clinical, Translational and Epidemiological Research
Current Diabetes Reviews Raloxifene and Cardiovascular Health: Its Relationship to Lipid and Glucose Metabolism, Hemostatic and Inflammation Factors and Cardiovascular Function in Postmenopausal Women
Current Pharmaceutical Design Pharmacological Implications of MMP-9 Inhibition by ACE Inhibitors
Current Medicinal Chemistry Modulation of Transient Receptor Potential Vanilloid Subtype 1 (TRPV<sub>1</sub>) and Norepinephrine Transporters (NET) Protect Against Oxidative Stress, Cellular Injury, and Vascular Dementia
Current Neurovascular Research Development of New Drugs that Act Through Membrane Receptors and Involve an Action of Inverse Agonism
Recent Patents on CNS Drug Discovery (Discontinued) Non-Alcoholic Fatty Liver Disease in HIV Infection Associated with Altered Hepatic Fatty Acid Composition
Current HIV Research